GET 73

Drug Profile

GET 73

Alternative Names: Gamma hydroxybutyric acid analogue; GET-73; GHB analogue

Latest Information Update: 06 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CT Laboratories
  • Class Anilides; Drug withdrawal therapies; Fluorobenzenes; Hydroxybutyrates; Neuroprotectants; Obesity therapies; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Alcoholism

Most Recent Events

  • 31 Jan 2018 Laboratorio Farmaceutico plans a phase II trial for Alcoholism in USA , (NCT03418623)
  • 21 Mar 2017 GET 73 is still in phase I/II trials for Alcoholism in USA
  • 01 Oct 2014 Phase-I/II clinical trials in Alcoholism (For alcohol dependence/alcohol withdrawal) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top